Market capitalization | $80.52m |
Enterprise Value | $53.80m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 0.80 |
P/S ratio (TTM) P/S ratio | 1.20 |
P/B ratio (TTM) P/B ratio | 1.58 |
Revenue growth (TTM) Revenue growth | 11.26% |
Revenue (TTM) Revenue | $67.04m |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
3 Analysts have issued a EDAP TMS SA Sponsored ADR forecast:
3 Analysts have issued a EDAP TMS SA Sponsored ADR forecast:
Jun '24 |
+/-
%
|
||
Revenue | 67 67 |
11%
11%
|
|
Gross Profit | 27 27 |
7%
7%
|
|
EBITDA | -22 -22 |
40%
40%
|
EBIT (Operating Income) EBIT | -22 -22 |
40%
40%
|
Net Profit | -21 -21 |
15%
15%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
EDAP TMS SA is a holding company, which through its subsidiary engages in the development, production, and marketing of minimally invasive medical devices for urological diseases. It operates through High Intensity Focused Ultrasound (HIFU) and Urology Devices and Services (UDS) segments. The HIFU segment develops, manufactures and markets devices for the minimally invasive ablation of certain types of localized tumors using HIFU technology. The UDS segment focuses in the development, marketing, manufacturing, and servicing of medical devices for the minimally invasive diagnosis or treatment of urological disorders, mainly urinary stones, and other clinical indications. The company was founded on December 3, 1979 and is headquartered in Vaulx-en-Velin, France.
Head office | France |
CEO | Ryan Rhodes |
Employees | 307 |
Founded | 1979 |
Website | www.edap-tms.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.